Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Paradoxical effects of apolipoprotein E on cognitive function and clinical progression in mice with experimental autoimmune encephalomyelitis.

Dayger CA, Rosenberg JS, Winkler C, Foster S, Witkowski E, Benice TS, Sherman LS, Raber J.

Pharmacol Biochem Behav. 2013 Feb;103(4):860-8. doi: 10.1016/j.pbb.2012.11.010. Epub 2012 Nov 30.

PMID:
23201649
2.

Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.

Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP.

J Pharmacol Exp Ther. 2006 Sep;318(3):956-65. Epub 2006 Jun 1.

3.

The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE).

Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, Baker GB, Kerr BJ.

Brain Behav Immun. 2011 Nov;25(8):1677-88. doi: 10.1016/j.bbi.2011.06.011. Epub 2011 Jun 22.

PMID:
21723939
4.

PSGL-1 is not required for development of experimental autoimmune encephalomyelitis.

Osmers I, Bullard DC, Barnum SR.

J Neuroimmunol. 2005 Sep;166(1-2):193-6.

PMID:
16005524
5.

EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE).

Munro KM, Dixon KJ, Gresle MM, Jonas A, Kemper D, Doherty W, Fabri LJ, Owczarek CM, Pearse M, Boyd AW, Kilpatrick TJ, Butzkueven H, Turnley AM.

PLoS One. 2013;8(2):e55948. doi: 10.1371/journal.pone.0055948. Epub 2013 Feb 4.

6.

Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.

Campbell AM, Zagon IS, McLaughlin PJ.

Brain Res. 2012 Sep 7;1472:138-48. doi: 10.1016/j.brainres.2012.07.006. Epub 2012 Jul 20.

PMID:
22820301
7.

Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice.

Thorne M, Moore CS, Robertson GS.

J Neuroimmunol. 2009 Jun 25;211(1-2):92-100. doi: 10.1016/j.jneuroim.2009.04.003. Epub 2009 May 9.

PMID:
19428125
8.

Altered cognitive-emotional behavior in early experimental autoimmune encephalitis--cytokine and hormonal correlates.

Acharjee S, Nayani N, Tsutsui M, Hill MN, Ousman SS, Pittman QJ.

Brain Behav Immun. 2013 Oct;33:164-72. doi: 10.1016/j.bbi.2013.07.003. Epub 2013 Jul 22.

PMID:
23886782
9.

Expression of scavenger receptor A on antigen presenting cells is important for CD4+ T-cells proliferation in EAE mouse model.

Levy-Barazany H, Frenkel D.

J Neuroinflammation. 2012 Jun 7;9:120. doi: 10.1186/1742-2094-9-120.

10.

Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).

Olechowski CJ, Tenorio G, Sauve Y, Kerr BJ.

Exp Neurol. 2013 Mar;241:113-21. doi: 10.1016/j.expneurol.2012.12.012. Epub 2013 Jan 2.

PMID:
23291347
11.

ApoE-deficient promotes blood-brain barrier disruption in experimental autoimmune encephalomyelitis via alteration of MMP-9.

Zheng M, Wei J, Tang Y, Yang C, Wei Y, Yin X, Liu Q.

J Mol Neurosci. 2014;54(2):282-90. doi: 10.1007/s12031-014-0291-x. Epub 2014 May 1.

PMID:
24788224
12.

Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE).

Moore CS, Hebb AL, Blanchard MM, Crocker CE, Liston P, Korneluk RG, Robertson GS.

J Neuroimmunol. 2008 Oct 15;203(1):79-93. doi: 10.1016/j.jneuroim.2008.06.030.

PMID:
18687476
13.

Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis.

Liu L, Huang D, Matsui M, He TT, Hu T, Demartino J, Lu B, Gerard C, Ransohoff RM.

J Immunol. 2006 Apr 1;176(7):4399-409.

14.

Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis.

Shin S, Walz KA, Archambault AS, Sim J, Bollman BP, Koenigsknecht-Talboo J, Cross AH, Holtzman DM, Wu GF.

J Neuroimmunol. 2014 Jun 15;271(1-2):8-17. doi: 10.1016/j.jneuroim.2014.03.010. Epub 2014 Mar 29.

15.

Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: correlation with incidence, onset and severity of disease.

Mazón Peláez I, Vogler S, Strauss U, Wernhoff P, Pahnke J, Brockmann G, Moch H, Thiesen HJ, Rolfs A, Ibrahim SM.

Hum Mol Genet. 2005 Jul 15;14(14):1977-89. Epub 2005 May 25.

PMID:
15917267
16.

APOE 4 polymorphism results in early cognitive deficits in an EAE model.

Tu JL, Zhao CB, Vollmer T, Coons S, Lin HJ, Marsh S, Treiman DM, Shi J.

Biochem Biophys Res Commun. 2009 Jul 10;384(4):466-70. doi: 10.1016/j.bbrc.2009.04.153. Epub 2009 May 5.

PMID:
19422789
17.

Role of circulating androgen levels in effects of apoE4 on cognitive function.

Pfankuch T, Rizk A, Olsen R, Poage C, Raber J.

Brain Res. 2005 Aug 16;1053(1-2):88-96.

PMID:
16054121
18.

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A.

J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y.

19.

Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination.

Farias AS, de la Hoz C, Castro FR, Oliveira EC, Ribeiro dos Reis JR, Silva JS, Langone F, Santos LM.

Neuroimmunomodulation. 2007;14(1):32-8. Epub 2007 Aug 15.

PMID:
17700038
20.

Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor.

Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, Shimizu T.

J Exp Med. 2005 Sep 19;202(6):853-63.

Supplemental Content

Support Center